ADDF's Diagnostics Accelerator
VC Fund
New York, United States
ADDF's Diagnostics Accelerator is a VC fund in New York focused on Biotechnology and Health Care. ADDF's Diagnostics Accelerator challenges the research community to develop cutting-edge biomarkers and explore novel diagnostic technologies.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries ADDF's Diagnostics Accelerator invests in
Stages ADDF's Diagnostics Accelerator invests in
Countries ADDF's Diagnostics Accelerator invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Health Care 2 (50%)
- Pharmaceutical 2 (50%)
- Life Science 1 (25%)
- Medical Device 1 (25%)
Stage
- Grant 1 (25%)
- Series A 1 (25%)
- Funding Round 1 (25%)
- Venture - Series Unknown 1 (25%)
Country
- Spain 1 (25%)
- Canada 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Superfluid Dx
|
Tissue-specific cell-free circulating RNA is a newly developed area for molecular diagnosis. Based on this powerful non-invasive approach, Molecular Stethoscope aims to transform healthcare by providing early insight into a patient’s healthy versus disease state. | Series A / Dec 20, 2023 | |
ADmit Therapeutics
|
ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with aneasy way to detect early-stage Alzheimer. | $6.1M / Venture - Series Unknown / Jul 19, 2023 | |
|
Superfluid Dx
|
Tissue-specific cell-free circulating RNA is a newly developed area for molecular diagnosis. Based on this powerful non-invasive approach, Molecular Stethoscope aims to transform healthcare by providing early insight into a patient’s healthy versus disease state. | Grant / Jun 07, 2022 | |
Optina Diagnostics
|
Optina Diagnostics develops technology for the early detection of disease through the eye. | $2.1M / Jan 24, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does ADDF's Diagnostics Accelerator invest in?
ADDF's Diagnostics Accelerator invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Grant and Series A stage. Most of the 4 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did ADDF's Diagnostics Accelerator last invest?
The most recent investment recorded for ADDF's Diagnostics Accelerator closed in Dec 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
